课题基金 / 基金详情

Molecular Regulation of Hepatic Transporters

Molecular Regulation of Hepatic Transporters
肝脏转运蛋白的分子调控
批准号:
7800419
负责人:
SAUL J. KARPEN
金额:
$27.92万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1999
资助国家:
美国
项目状态:
已结题
起止时间:
1999-09-01 至 2011-10-20
关键词:
AbbreviationsAcuteAcute-Phase ReactionAnionsAnti-Inflammatory AgentsAttenuatedBile AcidsBile fluidBindingCarrier ProteinsCationsCholestasisCholesterolCholic AcidsChronicCurcuminDataDeoxycholic AcidDexamethasoneDigestive System DisordersDirect RepeatsEffectivenessEnhancersFunctional disorderGene ExpressionGene ProteinsGenesGlucocorticoidsGlutathione S-TransferaseGoalsHepaticHepatobiliaryHepatocyteIn VitroIndividualInflammationInflammatoryInterleukin-1InterventionKnock-outLigandsLinkLipopolysaccharidesLithocholic AcidLiverLiver diseasesLocationMAPK8 geneMAPK9 geneMG132MapsMediatingMediator of activation proteinMembraneMembrane ProteinsMitogen-Activated Protein KinasesModelingModificationMolecularMolecular TargetMulti-Drug ResistanceMusNuclearNuclear ExportNuclear ReceptorsP-GlycoproteinsPathway interactionsPhospholipidsPhosphorylationPhosphotransferasesPhysiologicalPhysiologyPost-Translational Protein ProcessingPost-Translational RegulationProteasome InhibitionProteasome InhibitorProteinsPumpRXRReactionRegulationResearch PersonnelRetinoic Acid ReceptorReverse Transcriptase Polymerase Chain ReactionRoleSignal PathwaySignal TransductionSiteTestingTherapeutic InterventionTimeTranscription CoactivatorTranscription Factor AP-1Tumor Necrosis Factor-alphaTumor Necrosis FactorsUbiquitinUbiquitinationalitretinoinbasebile acid transporterbile saltscytokinedesignextracellularfunctional disabilityhepatocyte nuclear factorin vitro Modelin vivoinhibitor/antagonistmacromolecular assemblymembermulticatalytic endopeptidase complexnon-genomicnovel therapeuticspolypeptidepregnane X receptorpromoterprotein activationprotein expressionreceptorresearch studyresponserosiglitazonestress-activated protein kinase 1transcription factor

项目摘要

项目成果

SAUL J. KARPEN的其他基金

相似基金

相关文献

中文摘要
翻译
肝脏对炎症反应的中心特征之一是抑制一系列广泛的
英文摘要
One of the central features of the hepatic response to inflammation is the suppression of a broad array of core physiological functions, including those essential to maintaining hepatobiliary transport of bile acids. In addition to post-translational regulation of transporter protein membrane expression and function, inflammation-based cell signaling pathways act on nuclear targets to transcriptionally suppress the expression of the essential bile acid transporters Ntcp and Bsep. The central Type II NR superfamily member and heterodimer partner RXRa is a major transcriptional activator of these two genes, and its nuclear activity is rapidly suppressed by inflammation-based cell signaling. Reduced RXRa target gene expression leads to multiple functional impairments and damage to hepatocytes. How cell signaling pathways suppress RXRa function is unknown, and forms the basis for the explorations and interventions proposed in this application. The overall unifying hypothesis is that inflammatory cell signaling pathways reduce nuclear activity of RXRa via a coordinated cascade of post-translational modification, nuclear export and proteasomal degradation. The following four Aims will determine the underlying physiology, and pathophysiology of inflammation-mediated cholestasis and explore novel therapeutics. Aim 1: Define the molecular mechanisms mediating IL-1(3-induced nuclear export of RXRa. Aim 2: Determine roles for ubiquitination and proteasomal degradation of RXRa in response to IL-1 IB- induced signaling pathways. Aim 3: Explore crosstalk between bile acid and IL-1p-mediated pathways that modify RXRa function. Aim 4: Investigate the effects of anti-inflammatory agents on transporter gene and protein expression in the IPS model of hepatic inflammation. It is through a combined in vitro and in vivo approach that we can explore the mechanisms, mediators, and potential therapeutic interventions aimed at restoring RXRa function, hepatobiliary transporter function, and bile flow, in the setting of inflammation-mediated cell signaling in liver. The ultimate goal of these studies is to provide rational molecular targets for the testing of therapies specifically designed to interfere with the damaging consequences of inflammation-mediated pathways, which are engaged in nearly all forms of acute and chronic liver diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Modeling genetic contributions to biliary atresia
  • 批准号:
    10639240
  • 项目类别:
  • 资助金额:
    $64.01万
  • 财政年份:
    2023
  • 负责人:
    SAUL J. KARPEN
  • 依托单位:
Research Training in Translational Gastroenterology and Hepatology
  • 批准号:
    10410926
  • 项目类别:
  • 资助金额:
    $7.65万
  • 财政年份:
    2016
  • 负责人:
    SAUL J. KARPEN
  • 依托单位:
Research Training in Translational Gastroenterology and Hepatology
  • 批准号:
    9073070
  • 项目类别:
  • 资助金额:
    $15.23万
  • 财政年份:
    2016
  • 负责人:
    SAUL J. KARPEN
  • 依托单位:
Research Training in Translational Gastroenterology and Hepatology
  • 批准号:
    9280922
  • 项目类别:
  • 资助金额:
    $29.23万
  • 财政年份:
    2016
  • 负责人:
    SAUL J. KARPEN
  • 依托单位:
海外基金